Statins stand among the most vital and widely prescribed medications in modern medicine for preventing cardiovascular disease. By effectively lowering cholesterol levels in the bloodstream, these drugs have helped save millions of lives worldwide, significantly reducing the likelihood of debilitating heart attacks and strokes. Yet, despite their proven cardiovascular benefits, statin therapy can often come with unwanted and sometimes debilitating side effects. While many patients tolerate the medications well, a significant number develop persistent muscle pain, weakness, or fatigue. In a small fraction of cases, these adverse reactions escalate into serious muscle breakdown known as rhabdomyolysis, which can potentially lead to acute kidney failure and other life-threatening complications.
Now, a team of scientists at the University of British Columbia (UBC), working in close collaboration with colleagues at the University of Wisconsin-Madison, has successfully identified the precise molecular mechanism that helps explain these troublesome complications. Their landmark findings, which have been published in the prominent scientific journal Nature Communications, provide a crucial missing link in our understanding of how cholesterol-lowering drugs interact with human muscle tissue. This breakthrough could ultimately pave the way for the development of an entirely new generation of safer statins that maintain their powerful cholesterol-lowering benefits while minimizing or even eliminating muscle damage.
How Statins Trigger a Harmful Calcium Leak
To investigate what happens inside human muscle cells at a microscopic level, the research team utilized cryo-electron microscopy, a cutting-edge and advanced imaging technology. This sophisticated method allows scientists to examine macromolecular protein structures in remarkable detail, freezing biological samples in a fraction of a second to capture them in their natural states. The UBC-led investigation centered specifically on the ryanodine receptor, known scientifically as RyR1. This critical protein acts as an ion channel responsible for regulating the delicate movement and storage of calcium within muscle cells.
Under normal physiological conditions, the RyR1 protein functions as a strictly controlled gateway. It opens precisely when muscles need to contract and closes tightly when the contraction is complete. However, the researchers discovered that statins can severely interfere with this finely tuned process by aberrantly holding the channel open. As a direct consequence of this structural interference, calcium escapes continuously into areas of the muscle cell where it should be carefully regulated. This chronic, uncontrolled influx of calcium creates cellular conditions that can injure muscle tissue, causing the soreness, weakness, and pain reported by patients.
"We were able to see, almost atom by atom, how statins latch onto this channel," said lead author Dr. Steven Molinarolo, a postdoctoral researcher in UBC’s department of biochemistry and molecular biology. "That leak of calcium explains why some patients experience muscle pain or, in extreme cases, life-threatening complications."
Three Statin Molecules Reveal the Mechanism Behind Muscle Damage
During their investigation, the researchers concentrated heavily on atorvastatin, which is one of the most commonly prescribed medications in the world for lowering cholesterol and managing cardiovascular health. Although this particular drug served as the primary focus of the laboratory experiments, the team’s data strongly suggest that similar molecular interactions likely occur with other medications belonging to the broader statin family.
One of the most striking and unexpected discoveries to emerge from the imaging data was the unusual way statin molecules attach themselves to the calcium channel. Rather than acting as solitary agents, the researchers observed that three separate statin molecules simultaneously occupy a specific, specialized pocket within the RyR1 protein structure. The first molecule binds while the calcium channel is in a closed state, inadvertently altering the protein’s conformation and making it significantly more likely to open. Two additional statin molecules then enter the pocket in rapid succession, acting in concert to wedge the channel open and allowing calcium to continue leaking unabated into the cellular environment.
"This is the first time we’ve had a clear picture of how statins activate this channel," said Dr. Filip Van Petegem, senior author of the study and a professor at UBC’s Life Sciences Institute. "It’s a big step forward because it gives us a roadmap for designing statins that don’t interact with muscle tissue."
This unprecedented level of structural understanding could finally give pharmaceutical researchers a viable way to address the problem of muscle toxicity directly at its source. By modifying the specific chemical features and functional groups of statin molecules that interfere with human muscle proteins, scientists may soon be able to engineer new drug formulations. These future medications would reduce unwanted side effects without compromising the drugs’ essential ability to control cholesterol and protect the cardiovascular system.
A Potential Path Toward Safer Cholesterol Drugs
More than 200 million people worldwide rely on statin therapy to manage their cholesterol and safeguard their long-term heart health. Although severe muscle injury and rhabdomyolysis occur in only a small percentage of patients, less serious problems such as muscle soreness, generalized weakness, and persistent fatigue are considerably more widespread across the patient population. For many individuals, these physical symptoms can be disruptive and uncomfortable enough that they choose to discontinue their medication entirely. Stopping statin treatment prematurely leaves patients vulnerable, potentially stripping away critical protection against heart attacks and strokes.
The newly uncovered molecular mechanism could eventually help researchers create pharmacological treatments that are far easier for patients to tolerate. By eliminating or drastically reducing muscle-related side effects, more patients could remain compliant with their long-term prescriptions, maintaining uninterrupted protection against cardiovascular disease.
Achieving this high level of structural insight required exceptionally sophisticated technology and collaborative effort. Working with the high-resolution macromolecular cryo-electron microscopy facility housed within UBC’s faculty of medicine, the research team was able to observe precisely how statin molecules physically interact with the vital muscle protein. These clear structural insights successfully connect a longstanding drug safety concern that has puzzled physicians for decades to a specific, observable molecular process, providing invaluable guidance for future medication development programs.
"Statins have been a cornerstone of cardiovascular care for decades," Dr. Van Petegem noted. "Our goal is to make them even safer, so patients can benefit without fear of serious side effects."
Although additional biomedical research, preclinical testing, and extensive drug development will naturally be required before these laboratory findings successfully translate into tangible new clinical treatments, the discovery offers a profoundly promising direction for pharmacology. For the millions of individuals who depend on statins every day to protect their hearts, the prospect of future medications with significantly fewer muscle-related complications could make preventative healthcare much more comfortable and meaningfully improve everyday quality of life.